Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CILGAVIMAB\TIXAGEVIMAB Cause Product use issue? 94 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 94 reports of Product use issue have been filed in association with CILGAVIMAB\TIXAGEVIMAB. This represents 4.3% of all adverse event reports for CILGAVIMAB\TIXAGEVIMAB.

94
Reports of Product use issue with CILGAVIMAB\TIXAGEVIMAB
4.3%
of all CILGAVIMAB\TIXAGEVIMAB reports
26
Deaths
42
Hospitalizations

How Dangerous Is Product use issue From CILGAVIMAB\TIXAGEVIMAB?

Of the 94 reports, 26 (27.7%) resulted in death, 42 (44.7%) required hospitalization, and 1 (1.1%) were considered life-threatening.

Is Product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CILGAVIMAB\TIXAGEVIMAB. However, 94 reports have been filed with the FAERS database.

What Other Side Effects Does CILGAVIMAB\TIXAGEVIMAB Cause?

Covid-19 (521) Drug ineffective (123) Fatigue (86) Headache (86) Dyspnoea (84) Pyrexia (81) Nausea (68) Dizziness (64) Breakthrough covid-19 (51) Pneumonia (49)

What Other Drugs Cause Product use issue?

INFLIXIMAB (12,752) DUPILUMAB (10,575) POLYETHYLENE GLYCOL 3350 (9,432) METHOTREXATE (8,185) DICLOFENAC (8,009) RITUXIMAB (6,948) ADALIMUMAB (6,379) ETANERCEPT (6,062) TOCILIZUMAB (5,944) ABATACEPT (5,915)

Which CILGAVIMAB\TIXAGEVIMAB Alternatives Have Lower Product use issue Risk?

CILGAVIMAB\TIXAGEVIMAB vs CILOSTAZOL CILGAVIMAB\TIXAGEVIMAB vs CILTACABTAGENE AUTOLEUCEL CILGAVIMAB\TIXAGEVIMAB vs CIMETIDINE CILGAVIMAB\TIXAGEVIMAB vs CIMZIA CILGAVIMAB\TIXAGEVIMAB vs CINACALCET

Related Pages

CILGAVIMAB\TIXAGEVIMAB Full Profile All Product use issue Reports All Drugs Causing Product use issue CILGAVIMAB\TIXAGEVIMAB Demographics